Skip to main content

Kevin Charles Oeffinger

Professor of Medicine
Medicine, Medical Oncology
Box 2714 DUMC, Durham, NC 27705
2424 Erwin Dr, Suite 601, Duke Cancer Institute, Durham, NC 27705

Overview


Kevin Oeffinger, MD, is a family physician, Professor in the Department of Medicine, and a member of the Duke Cancer Institute (DCI). He is founding Director of the DCI Center for Onco-Primary Care, and Director of the DCI Supportive Care and Survivorship Center. He has a long-standing track record of NIH-supported research in cancer screening and survivorship and has served in a leadership capacity in various cancer-focused and primary care-focused national committees and organizations, including the American Society of Clinical Oncology, the American Cancer Society, and the American Academy of Family Physicians. He is currently an Associate Editor for the Journal of the National Cancer Institute.

The three-fold mission of the DCI Center for Onco-Primary Care are are to: (1) deliver evidence-based, patient-centered, personalized health care across the cancer continuum by enhancing the interface between cancer specialists and primary care clinicians; (2) conduct innovative research with cutting-edge technology that can be translated to the community setting; and (3) train and educate the next generation of clinicians and researchers to extend this mission. 

Dr. Oeffinger's clinical expertise is managing survivors of pediatric and young adult cancer.

Current Appointments & Affiliations


Professor of Medicine · 2018 - Present Medicine, Medical Oncology, Medicine
Professor in the Department of Family Medicine and Community Health · 2018 - Present Family Medicine and Community Health, Clinical Science Departments
Professor in Population Health Sciences · 2020 - Present Population Health Sciences, Basic Science Departments
Member of the Duke Cancer Institute · 2017 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy

Journal Article Jacc Cardiooncology · June 1, 2025 Background: Echocardiograms are recommended every 3 months to monitor for cancer therapy–related cardiac dysfunction (CTRCD) among patients treated with HER2-targeted therapy, despite increasing use of safer regimens associated with low CTRCD risk. Objecti ... Full text Cite

Accelerated Aging in Survivors of Childhood Cancer-Early Onset and Excess Risk of Chronic Conditions.

Journal Article JAMA Oncol · May 1, 2025 IMPORTANCE: The lifetime risk of aging-related diseases among survivors of childhood cancer, accelerated by cancer treatment exposures, is unknown. Understanding this risk can provide a more comprehensive assessment of long-term health across the lifespan ... Full text Link to item Cite
View All Publications

Recent Grants


PATHFINDER 2

Clinical TrialPrincipal Investigator · Awarded by GRAIL · 2022 - 2027

View All Grants

Education, Training & Certifications


University of Texas Health Science Center San Antonio · 1984 M.D.